Date: 2013-12-17
Type of information: Initiation of preclinical development
phase: preclinical
Announcement: initiation of the development of an inhaled form
Company: NovaBiotics (UK)
Product: inhaled form of Lynovex
Action
mechanism: Lynovex is an orphan drug candidate that breaks down mucus, disrupts and prevents bacterial films and acts as an antibacterial against Gram-negative and Gram-positive respiratory bacteria.
Disease: cystic fibrosis
Therapeutic area: Rare diseases - Genetic diseases
Country:
Trial details:
Latest
news: * On December 17, 2013, NovaBiotics, an Aberdeen-based clinical-stage biotechnology company, has announced it has initiated the development of an inhaled form of Lynovex®, its treatment for cystic fibrosis. NovaBiotics is working with inhalation formulation specialists at Crystec in Bradford, UK to develop dry powder inhalable forms of the drug. The aim of administering the drug by aerosolisation is to deliver maximum efficiency with lower doses of the treatment targeted directly to the relevant areas of the respiratory tract.
As a maintenance therapy, the inhaled form of Lynovex is intended for the long term control of the chronic lung infections and mucus production associated with cystic fibrosis. In addition, NovaBiotics is investigating a tablet form for Lynovex for use in acute exacerbations of cystic fibrosis and is working with NHS Grampian and the University of Aberdeen’s cystic fibrosis research team to undertake a phase IIa clinical trial of this new formulation, commencing in early 2014.
NovaBiotics’ collaboration with the Cystic Fibrosis Trust to fund the upcoming phase IIa study will be highlighted as a case study at the UK Bioindustry Association’s Annual Parliament Day on 30 January 2014, a flagship advocacy event which represents the sector’s top policy needs to senior policymakers across government and sets the agenda for the year ahead.
